FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage

Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding. 

​ 

Leave a Reply

Your email address will not be published. Required fields are marked *

Search this website